Quidel to Present at 36th Annual J.P. Morgan Healthcare Conference
December 21 2017 - 6:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a
provider of rapid diagnostic testing solutions, cell-based virology
assays and molecular diagnostic systems, announced today that it
will present at the 36th Annual J.P. Morgan Healthcare Conference
to be held at The Westin St. Francis hotel in San Francisco,
California on Wednesday, January 10, 2018.
Douglas Bryant, president and chief executive officer,
and Randy Steward, chief financial officer, will present that
day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
with a question and answer session scheduled immediately following
the presentation. During the presentation, the company will discuss
business and financial developments and trends. The company's
statements may contain or constitute material information that has
not been previously disclosed.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company's Web
site at http://ir.quidel.com/, or by accessing the following
link:
https://jpmorgan.metameetings.net/events/healthcare18/sessions/13316-quidel-corporation/webcast
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company's Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and
well-being of people around the globe through the development of
diagnostic solutions that can lead to improved patient outcomes and
provide economic benefits to the healthcare system. Marketed under
the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage®
and InflammaDry® leading brand names, as well as under the new
Solana®, AmpliVue® and Lyra® molecular diagnostic brands,
Quidel’s products aid in the detection and diagnosis of many
critical diseases and conditions, including, among
others, influenza, respiratory syncytial virus, Strep A,
herpes, pregnancy, thyroid disease and fecal occult
blood. Quidel's recently acquired Triage® system of tests
comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide you with diagnostic answers for quantitative BNP, CK-MB,
d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen.
Quidel’s research and development engine is also developing a
continuum of diagnostic solutions from advanced immunoassay to
molecular diagnostic tests to further improve the quality of
healthcare in physicians’ offices and hospital and reference
laboratories. For more information about Quidel’s comprehensive
product portfolio, visit quidel.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171221006095/en/
Quidel CorporationQuidel Contact:Randy Steward,
858-552-7931Chief Financial OfficerorMedia and Investors
Contact:Ruben Argueta, 858-646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024